申请人:BASF Aktiengesellschaft
公开号:US06001839A1
公开(公告)日:1999-12-14
Compounds of formula I ##STR1## including pharmaceutically acceptable salts thereof in which R.sub.1 represents hydrogen, 2-phenyl-1,3-dioxan-5-yl, a C.sub.1-6 alkyl group, a C.sub.3-8 cycloalkyl group, a C.sub.5-7 cycloalkenyl group or an (optionally substituted phenyl)C.sub.1-6 alkyl group wherein the alkyl, cycloalkyl and cycloalkenyl groups are optionally substituted by one or more groups of formula OR.sub.A in which R.sub.A represents H or a C.sub.1-6 alkyl group provided that a group of formula OR.sub.A is not located on the carbon attached to nitrogen; R.sub.2 represents hydrogen, a C.sub.1-6 alkyl group, a C.sub.3-8 cycloalkyl group, halo, hydroxy, an (optionally substituted phenyl)C.sub.1-6 alkyl group, optionally substituted phenyl or R.sub.4 ; and R.sub.3 represents a group of formula (a) ##STR2## in which the phenyl ring is additionally optionally substituted and A represents NH, O, NHSO.sub.2, SO.sub.2 NH, a C.sub.1-4 alkylene chain, NHCO, NHCO.sub.2, CONH, NHCONH, CO.sub.2 or S(O).sub.p in which p is 0, 1 or 2, or A is absent and R.sub.5 is attached directly to the phenyl ring; and R.sub.5 represents optionally substituted phenyl and, additionally, when A is absent R.sub.5 represents a) a phthalimido group optionally substituted by halo or b) a pyrazolylamino group in which the pyrazole ring is optionally substituted by one or more of the following: hydroxy or optionally substituted phenyl; R.sub.4 represents a heterocyclic group; are described which are useful in treating proliferative diseases and disorders of the immune system in mammals. Processes to prepare these compounds and pharmaceutical compositions containing these compound are also described.
该文描述了公式I的化合物,其中包括其药学上可接受的盐。其中R1代表氢、2-苯基-1,3-二氧杂
环戊烷-5-基、C1-6烷基、C3-8环烷基、C5-7环烯基或(可选取代苯基)C1-6烷基,其中烷基、环烷基和环烯基基团可以被一个或多个OR_A基团取代,其中R_A代表H或C1-6烷基,但OR_A基团不能位于连接氮的碳上;R2代表氢、C1-6烷基、C3-8环烷基、卤素、羟基、(可选取代苯基)C1-6烷基、可选取代苯基或R4;R3代表公式(a)的基团,其中苯环还可以是可选取代的,A代表NH、O、NHSO2、SO2NH、C1-4烷基链、NHCO、NH 、CONH、NHCONH、
CO2或S(O)p,其中p为0、1或2,或A不存在且R5直接连接苯环;R5代表可选取代的苯基,此外,当A不存在时,R5表示a)可选取代的邻苯二甲
酰亚胺基团,可选取代为卤素或b)
吡唑基
氨基基团,其中
吡唑环可以选择一个或多个以下基团取代:羟基或可选取代苯基;R4代表杂环基团。这些化合物可用于治疗哺乳动物的增殖性疾病和免疫系统紊乱。文中还描述了制备这些化合物的方法和含有这些化合物的药物组合物。